Role of active surveillance and focal therapy in low- and intermediate-risk prostate cancers

被引：0
|
作者：
Henk van der Poel
Laurence Klotz
Gerald Andriole
Abdel-Rahmène Azzouzi
Anders Bjartell
Olivier Cussenot
Freddy Hamdy
Markus Graefen
Paolo Palma
Arturo Rodriguez Rivera
Christian G. Stief
机构：
[1] Netherlands Cancer Institute,Department of Urology
[2] University of Toronto,Division of Urology, Sunnybrook Health Science Centre
[3] Washington University St Louis,Division of Urology, Department of Surgery
[4] CHU d’Angers,Service d’Urologie
[5] Sahlgrenska Academy at the University of Gothenburg,Department of Urology, Institute of Clinical Sciences
[6] UPMC Univ Paris 06,Institute Universitaire de Cancerologie
[7] GRC-05,Nuffield Department of Surgical Sciences
[8] ONCOTYPE-Uro,Martini
[9] University of Oxford,Clinic Prostate Cancer Center
[10] University Medical Center Hamburg-Eppendorf,Department of Urology
[11] Universidade Estadual de Campinas,Department of Urology, Klinikum Großhadern, University Hospital Munich
[12] Hospital General Tlahuac,Großhadern
[13] Ludwig-Maximillians-University München,undefined
来源：
World Journal of Urology | 2015年 / 33卷
关键词：
Prostate cancer; Focal therapy; Active surveillance; Low risk; Intermediate risk; Consensus;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：907 / 916
页数：9
相关论文
共 50 条
  • [41] Safety and Feasibility of Transperineal Targeted Microwave Ablation for Low- to Intermediate-risk Prostate Cancer
    Oderda, Marco
    Marquis, Alessandro
    Calleris, Giorgio
    D'Agate, Daniele
    Faletti, Riccardo
    Gatti, Marco
    Marra, Giancarlo
    Gontero, Paolo
    EUROPEAN UROLOGY OPEN SCIENCE, 2022, 46 : 3 - 7
  • [42] Surveillance after prostate focal therapy
    Tay, Kae Jack
    Amin, Mahul B.
    Ghai, Sangeet
    Jimenez, Rafael E.
    Kench, James G.
    Klotz, Laurence
    Montironi, Rodolfo
    Muto, Satoru
    Rastinehad, Ardeshir R.
    Turkbey, Baris
    Villers, Arnauld
    Polascik, Thomas J.
    WORLD JOURNAL OF UROLOGY, 2019, 37 (03) : 397 - 407
  • [43] Active Surveillance for Intermediate-risk Prostate Cancer: A Systematic Review, Meta-analysis, and Metaregression
    Baboudjian, Michael
    Breda, Alberto
    Rajwa, Pawel
    Gallioli, Andrea
    Gondran-Tellier, Bastien
    Sanguedolce, Francesco
    Verri, Paolo
    Diana, Pietro
    Territo, Angelo
    Bastide, Cyrille
    Spratt, Daniel E.
    Loeb, Stacy
    Tosoian, Jeffrey J.
    Leapman, Michael S.
    Palou, Joan
    Ploussard, Guillaume
    EUROPEAN UROLOGY ONCOLOGY, 2022, 5 (06): : 617 - 627
  • [44] Impact of 18F-DCFPyL PET/MRI in Selecting Men With Low-/Intermediate-Risk Prostate Cancer for Focal Ablative Therapies
    Dias, Adriano Basso
    Ghai, Sangeet
    Ortega, Claudia
    Mirshahvalad, Seyed Ali
    Perlis, Nathan
    Berlin, Alejandro
    Avery, Lisa
    Veit-Haibach, Patrick
    van der Kwast, Theodorus
    Metser, Ur
    CLINICAL NUCLEAR MEDICINE, 2023, 48 (10) : E462 - E467
  • [45] A Systematic Review on Prostate-Specific Membrane Antigen Positron Emission Tomography (PSMA PET) Evaluating Localized Low- to Intermediate-Risk Prostate Cancer: A Tool to Improve Risk Stratification for Active Surveillance?
    Liu, Jianliang
    Santucci, Jordan
    Woon, Dixon T. S.
    Catterwell, Rick
    Perera, Marlon
    Murphy, Declan G.
    Lawrentschuk, Nathan
    LIFE-BASEL, 2024, 14 (01):
  • [46] How can we expand active surveillance criteria in patients with low- and intermediate-risk prostate cancer without increasing the risk of misclassification? Development of a novel risk calculator
    Gandaglia, Giorgio
    van den Bergh, Roderick C. N.
    Tilki, Derya
    Fossati, Nicola
    Ost, Piet
    Surcel, Christian I.
    Sooriakumaran, Prasanna
    Tsaur, Igor
    Valerio, Massimo
    Kretschmer, Alexander
    Zaffuto, Emanuele
    Salomon, Laurent
    Montorsi, Francesco
    Graefen, Markus
    van der Poel, Henk
    de la Taille, Alexandre
    Briganti, Alberto
    Ploussard, Guillaume
    BJU INTERNATIONAL, 2018, 122 (05) : 823 - 830
  • [47] Four-year quality-of-life outcomes in low- to intermediate-risk prostate cancer patients following definitive stereotactic body radiotherapy versus management with active surveillance
    Monaco, Ashley
    Sommer, Jessica
    Akerman, Meredith
    Lischalk, Jonathan W.
    Haas, Jonathan
    Corcoran, Anthony
    Katz, Aaron
    WORLD JOURNAL OF UROLOGY, 2022, 40 (09) : 2213 - 2219
  • [48] Four-year quality-of-life outcomes in low- to intermediate-risk prostate cancer patients following definitive stereotactic body radiotherapy versus management with active surveillance
    Ashley Monaco
    Jessica Sommer
    Meredith Akerman
    Jonathan W. Lischalk
    Jonathan Haas
    Anthony Corcoran
    Aaron Katz
    World Journal of Urology, 2022, 40 : 2213 - 2219
  • [49] Use and early mortality outcomes of active surveillance in patients with intermediate-risk prostate cancer
    Butler, Santino S.
    Mahal, Brandon A.
    Lamba, Nayan
    Mossanen, Matthew
    Martin, Neil E.
    Mouw, Kent W.
    Nguyen, Paul L.
    Muralidhar, Vinayak
    CANCER, 2019, 125 (18) : 3164 - 3171
  • [50] Is There a Role for Active Surveillance in Low-Risk Prostate Cancer?
    Augustin, Herbert
    Mayerhofer, Katrin
    Seles, Maximilian
    Pummer, Karl
    UROLOGIA INTERNATIONALIS, 2015, 95 (02) : 125 - 131
12345